RELATIONSHIP OF-31G/C (rs9904341) POLYMORPHISM IN THE SURVIVIN GENE BIRC5 AND THE RISK OF BLADDER CANCER | Научно-инновационный портал СФУ

RELATIONSHIP OF-31G/C (rs9904341) POLYMORPHISM IN THE SURVIVIN GENE BIRC5 AND THE RISK OF BLADDER CANCER

Тип публикации: статья из журнала

Год издания: 2022

Идентификатор DOI: 10.21294/1814-4861-2022-21-4-64-71

Ключевые слова: bioluminescent analysis, bladder cancer, single nucleotide polymorphism (snp) rs9904341, survivin

Аннотация: Purpose: To study the relationship between the-31G/C (rs9904341) polymorphism in the promoter region of the survivin protein gene and the predisposition to bladder cancer (BC) in patients of the Krasnoyarsk region. Material and methods. The allelic composition of the studied gene was determined in a group of 158 BC patients, consisting of 30 women and 128 men (mean age 65.6 ± 10.7, median: 66.5; C25 –C75: 59–72). The control group included 117 healthy donors and consisted of 27 women and 90 men with an average age of 60.2 ± 5.1 (median: 60; C25 –C75: 57–63.25). The allelic composition was determined using the biolumines-cent method. A sample with the GC genotype confirmed by Sanger sequencing (Center for Collective Use “Genomika”, Novosibirsk, Russia) was used as a control. The Mann–Whitney U test was used to compare quantitative data. The studied sample was in Hardy–Weinberg equilibrium (p>0.5). The Pearson χ2 test was used to compare the frequencies of gene variants among BC cases and control samples. The association between variants rs9904341 and BC was assessed in terms of odds ratio (OR) with a 95 % confidence in-terval (CI); p values<0.05 were considered significant. Results. The allelic composition was determined for the genes of patients and control group participants: GG – 62 (39.2%) vs 43 (36.8%); GC – 82 (51.9%) vs 54 (46.2%); CC – 14 (8.9%) vs 20 (17.15%). The relationship between the presence of the C allele and BC was assessed using the recessive inheritance model, combining all carriers – heterozygotes and homozygotes. The frequency of occurrence of genotypes for patients and the control group was established: GG + GC – 144 (91.1%) vs 97 (82.9%); CC – 14 (8.9%) vs 20 (17.1%). Thus, carriers of the CС genotype were significantly less in patients: OR (95% CI) 0.47 (0.23–0.98), p=0.04. The relationship with tumor invasion was not significant (p=0.08). Conclusion. Based on the results of detecting the rs9904341 (G/C) polymorphism among BC patients of the Krasnoyarsk region, a protective effect of the carriage of the CC genotype was found. In order to study the allelic composition with the threat of recurrence of the disease, additional research is needed. © 2022, Tomsk National Research Medical Center of the Russian Academy of Sciences. All rights reserved.

Ссылки на полный текст

Издание

Журнал: Siberian Journal of Oncology

Выпуск журнала: Vol. 21, Is. 4

Номера страниц: 64-71

ISSN журнала: 18144861

Издатель: Tomsk National Research Medical Center of the Russian Academy of Sciences

Персоны

  • Bashmakova E.E. (Institute of Biophysics, Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences, 50/50, Akademgorodok, Krasnoyarsk, 660035, Russian Federation)
  • Panamarev N.S. (Institute of Biophysics, Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences, 50/50, Akademgorodok, Krasnoyarsk, 660035, Russian Federation, Siberian Federal University, 79, Svobodny Ave., Krasnoyarsk, 660041, Russian Federation)
  • Kudryavtsev A.N. (Institute of Biophysics, Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences, 50/50, Akademgorodok, Krasnoyarsk, 660035, Russian Federation)
  • Chernyaev D.V. (Regional Clinical Oncology Center named after A.I. Kryzhanovsky, 16, Smolenskaya St., Krasnoyarsk, 660133, Russian Federation, State Medical University named after V.F. Voyno-Yasenetsky of the Ministry of Health of Russia, 1, Partizana Zheleznyaka St., Krasnoyarsk, 660022, Russian Federation)
  • Slepov E.V. (Regional Clinical Oncology Center named after A.I. Kryzhanovsky, 16, Smolenskaya St., Krasnoyarsk, 660133, Russian Federation)
  • Zukov R.A. (Regional Clinical Oncology Center named after A.I. Kryzhanovsky, 16, Smolenskaya St., Krasnoyarsk, 660133, Russian Federation, State Medical University named after V.F. Voyno-Yasenetsky of the Ministry of Health of Russia, 1, Partizana Zheleznyaka St., Krasnoyarsk, 660022, Russian Federation)
  • Frank L.A. (Institute of Biophysics, Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences, 50/50, Akademgorodok, Krasnoyarsk, 660035, Russian Federation, Siberian Federal University, 79, Svobodny Ave., Krasnoyarsk, 660041, Russian Federation)

Вхождение в базы данных

Информация о публикациях загружается с сайта службы поддержки публикационной активности СФУ. Сообщите, если заметили неточности.

Вы можете отметить интересные фрагменты текста, которые будут доступны по уникальной ссылке в адресной строке браузера.